IGNT.US Ingen Technologies
- Market cap
- USD 16.7K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending May 2015.
Is IGNT.US undervalued?
Graham numberThe Graham number of Ingen Technologies cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Ingen Technologies fundamental analysis
No fundamental analysis for Ingen Technologies yet.
Ingen Technologies stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Ingen Technologies
Ingen Technologies, Inc. engages in the research and development of home healthcare products for the respiratory industry in United States. It offers oxygen flow meters and nasal cannulas under the Oxyview and Smart Nasal Cannula trademark names for patients suffering with chronic obstructive pulmonary disease. The company was founded in 1999 and is based in Riverside, California.
Full company profileIngen Technologies financial statements
Ingen Technologies annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 847K | 721K | 252K | 10.4K | 129K | 44.4K | 13.4K | 3.22K | 6.31K | 13.57 |
| Gross Profit | 546K | 269K | 84.9K | -37.9K | 83.3K | 23.2K | 7.00K | -9.77K | 4.87K | 12.98 |
| Operating Income | -1.60M | -1.61M | -1.66M | -2.02M | -2.68M | -1.25M | -7.42K | -13.2K | -362K | -654.00 |
| EBITDA | -1.58M | -8.64K | 25.4K | -2.05M | 6.18M | -1.21M | -714K | -550K | -362K | 0.75 |
| Net Income | -1.60M | -5.06M | -1.30M | -5.07M | -6.30M | -2.18M | -1.12M | -1.16M | -782K | -1.01K |
| EPS | - | - | - | -129 | -2.15 | -0.26 | 0.00 | -0.67 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 363K | 738K | 827K | 441K | 580K | 314K | 147K | 326K | 279K | 318.62 |
| Total Liabilities | 299K | 5.71M | 5.35M | 11.4M | 5.55M | 6.90M | 9.60M | 7.45M | 11.0M | 11.1K |
| Shareholders' Equity | 63.9K | -4.97M | -4.52M | -11.0M | -4.97M | -6.58M | -9.45M | -7.12M | -10.8M | -10.8K |
| Cash & Short-term Investments | 111K | 238.00 | - | 42.3K | 269K | 6.10K | 336.00 | 83.00 | 1.17K | 0.00 |
| Total Debt | 70.8K | 631K | 1.33M | 3.67M | 1.73M | 1.96M | 4.76M | 2.62M | 8.02M | 6.71K |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.49M | -1.32M | -659K | -879K | -2.24M | 6.62M | 6.62M | -668K | -39.5K | 6.62K |
| Capital Expenditure | 24.7K | 345K | 3.00 | 0.00 | 13.8K | 0.00 | 1.73K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -1.51M | -1.67M | -659K | -879K | -2.25M | - | - | -668K | -39.5K | 6.62K |
| Ratios | ||||||||||
| ROE | -2,506.6% | - | - | - | - | - | - | - | - | - |
| ROA | -441.9% | -686.1% | -157.5% | -1,148.1% | -1,086.5% | -694.8% | -764.4% | -355.3% | -279.9% | -317.6% |
| Net Profit Margin | -189.3% | -702.3% | -516.2% | -48,712.4% | -4,888.7% | -4,910.0% | -8,361.3% | -35,960.0% | -12,387.7% | -7,457.6% |
| Debt to Equity | 1.11x | - | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Ingen Technologies dividends
Ingen Technologies has not paid dividends in the last 10 fiscal years.
Last stock split: 1:1000 on Nov 22, 2010.
Who owns Ingen Technologies
Ownership data of Ingen Technologies is not available yet.
Ingen Technologies company profile
- Company name
- Ingen Technologies
- Ticker
- IGNT.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- May
- Address
- 3410 La Sierra Avenue, Riverside, CA, United States, 92503
- Phone
- 951-688-7840
- Website
- ingen-tech.com
About Ingen Technologies
Ingen Technologies, Inc. engages in the research and development of home healthcare products for the respiratory industry in United States. It offers oxygen flow meters and nasal cannulas under the Oxyview and Smart Nasal Cannula trademark names for patients suffering with chronic obstructive pulmonary disease. The company was founded in 1999 and is based in Riverside, California.
Ingen Technologies management
3- Mr. Gary B. TildenChairman of the Board, COO & Secretary · born 1955
- Mr. David S. HansonCEO & Director · born 1946
- Mr. Richard O. WeedGeneral Counsel · born 1962